Colonic Neoplasms × Head & Neck × Clear all
NCT02432963 2026-01-28

Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy

City of Hope Medical Center

Phase 1 Active not recruiting
11 enrolled
NCT02012699 2026-01-22

iCaRe2

University of Nebraska

Recruiting
999,999 enrolled
NCT03899792 2026-01-06

LIBRETTO-121

Eli Lilly and Company

Phase 1/2 Active not recruiting
36 enrolled 13 charts 2 FDA
NCT05544929 2026-01-06

A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers

Novartis

Phase 1 Active not recruiting
126 enrolled
NCT06171945 2025-10-27

AYAConnect

UNC Lineberger Comprehensive Cancer Center

Phase NA Completed
63 enrolled
NCT03157128 2025-10-20

LIBRETTO-001

Eli Lilly and Company

Phase 1/2 Active not recruiting
857 enrolled 3 FDA
NCT05461430 2025-09-15

TraveraRTGx

Travera Inc

Recruiting
200 enrolled
NCT03093116 2025-07-10

TRIDENT-1

Turning Point Therapeutics, Inc.

Phase 1/2 Recruiting
500 enrolled 2 FDA
NCT06239194 2025-06-22

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

ModeX Therapeutics, An OPKO Health Company

Phase 1/2 Recruiting
115 enrolled
NCT03037385 2025-05-31

ARROW

Hoffmann-La Roche

Phase 1/2 Completed
590 enrolled 58 charts 5 FDA
NCT06673329 2025-05-14

Brodalumab in the Treatment of Immune-Related Adverse Events

Columbia University

Phase 1 Recruiting
11 enrolled
NCT05179824 2025-05-06

Tempus Priority Study: A Pan-tumor Observational Study

Tempus AI

Active not recruiting
1,000 enrolled
NCT03301493 2025-04-10

Genomic Testing and Resulting Medical Decisions

Arbeitsgemeinschaft medikamentoese Tumortherapie

Completed
1,500 enrolled
NCT06787807 2025-01-22

Proteomic Analysis of Patients Undergoing Bariatric Surgery

Universidade Federal de Pernambuco

Phase NA Not yet recruiting
103 enrolled
NCT06583395 2024-11-01

QUANTUM

VitaMed Research LLC

Enrolling by invitation
3,000 enrolled
NCT03602079 2023-08-03

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Klus Pharma Inc.

Phase 1/2 Completed
49 enrolled
NCT05708950 2023-07-13

A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)

Kineta Inc.

Phase 1/2 Unknown
314 enrolled